Iceland· IS-EU/1/20/1514/001
Inrebic
A fedratinib product containing fedratinibum inn, registered in Iceland by Bristol-Myers Squibb Pharma EEIG*. The same ATC class is registered in 12 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Fedratinib is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EJ02 (fedratinib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 7 of them publish a price we can compare per daily dose
Fedratinib · ATC L01EJ02
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Fedratinibum INN
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG*
- Country
- Iceland (IS)
- ATC code
- L01EJ02
- ATC class
- Fedratinib
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
554 interactions on record for fedratinib.
Graded by severity as the source publishes them — 161 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fedratinib · interactions on record
554 records
- 161 severe
- 370 moderate
- 23 minor
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- EliglustatA16AX10severe
- LonafarnibA16AX20severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Fedratinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesInrebicCelgene Corporation
- CanadaINREBICBRISTOL-MYERS SQUIBB CANADA
- CzechiaINREBICBristol-Myers Squibb Pharma EEIG, Dublin
- SpainINREBIC 100 mg CAPSULAS DURASBristol-Myers Squibb Pharma Eeig
- FinlandInrebicBristol-Myers Squibb Pharma EEIG
- FranceINREBIC 100 mg, géluleBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- BelgiumInrebic 100 mgBristol-Myers Squibb Pharma
- NetherlandsInrebic 100 mg, harde capsulesBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Inrebic
- Norway · Inrebic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/aadb923d-7a5c-404c-a2f4-7c50097566e9 GET /v1/drugs/aadb923d-7a5c-404c-a2f4-7c50097566e9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Hart hylki",
"source": "lyfjastofnun",
"atc_raw": "L01EJ02",
"marketed": false,
"strength": "100 mg",
"ma_number": "EU/1/20/1514/001",
"substance": "Fedratinibum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í blóðsjúkdómum og krabbameinslækningum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "44235"
}See everything about fedratinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.